Roche Says Illumina Takeover Would Hasten Sequencing’s Path To Diagnostics

With $5.7 billion hostile takeover attempt for next-generation gene sequencing powerhouse Illumina, Roche says it is uniquely situated to push sequencing into the routine clinical diagnostics space. But Illumina is resisting, which could push up the price and draw out the process.

Roche’s hostile takeover bid for next-generation gene sequencing powerhouse Illumina is aimed not merely at growing its diagnostics business but at accelerating the move of whole-genome sequencing from research to clinical use, according to the company.

“There’s clearly a gap today and that is the ability for sequencing to be used in routine in-vitro diagnostics,” said...

More from Deals

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By 

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

More from Business